07:00 , Jul 23, 2012 |  BC Week In Review  |  Clinical News

AclarusDx: Completed enrollment

Exonhit completed enrollment of 600 patients complaining of cognitive disorders or memory impairment in the French DIALOG trial evaluating AclarusDx. The product has CE Mark approval and is available in France. ExonHit S.A. (Euronext:ALEHT), Paris,...
07:00 , Jul 23, 2012 |  BC Week In Review  |  Clinical News

AclarusDx: Pilot trial completed enrollment

Exonhit completed enrollment of 160 newly referred patients with memory impairment in a U.S. pilot trial evaluating AclarusDx. The product has CE Mark approval and is available in France. ExonHit S.A. (Euronext:ALEHT), Paris, France   Product:...
08:00 , Nov 7, 2011 |  BC Week In Review  |  Clinical News

AclarusDx: Pilot trial started

This month, ExonHit will begin a U.S. pilot trial to evaluate AclarusDx in 160 patients with memory impairment. The product has CE Mark approval and is available in France. ExonHit S.A. (Euronext:ALEHT), Paris, France   Product:...
07:00 , Mar 21, 2011 |  BC Week In Review  |  Clinical News

AclarusDx Alz test regulatory update

ExonHit received CE mark approval for its AclarusDx blood-based Alzheimer's disease (AD) diagnostic test. The company plans to launch the test this year. ExonHit Therapeutics S.A. (Euronext:ALEHT), Paris, France   Product: AclarusDx Alz test (formerly...
01:40 , Dec 17, 2009 |  BC Extra  |  Financial News

ExonHit raises EUR 15.6 million

ExonHit Therapeutics S.A. (Euronext:ALEHT) raised EUR 15.6 million ($22.9 million) through the sale of 4.2 million shares at EUR 3.75. The price is a 21% discount to ExonHit's close of EUR 4.75 on Dec. 4,...
08:00 , Nov 9, 2009 |  BC Week In Review  |  Clinical News

AclarusDx diagnostic data

Data from a validation study in 110 patients with AD and 101 healthy volunteers showed that AclarusDx correctly identified 74% of AD patients with an overall accuracy of 71%. When samples with ambiguous expression profile...
08:00 , Nov 9, 2009 |  BC Week In Review  |  Clinical News

AclarusDx: Study ongoing

ExonHit said that it will participate in the 3-year, double-blind, placebo-controlled, French MAPT trial in 1,200 elderly individuals. The investigator-led study is designed to evaluate the effect of omega-3 fatty acid supplementation with or without...